GSK, Vir Say U.S. to Buy Added Supply of Covid Treatment
12 January 2022 - 12:10AM
Dow Jones News
By Michael Dabaie
GlaxoSmithKline PLC and Vir Biotechnology Inc. said the U.S.
government will purchase an additional 600,000 doses of sotrovimab,
an investigational monoclonal antibody for the early treatment of
Covid-19.
The companies said the additional 600,000 doses would be
delivered throughout the first quarter of 2022. The agreement is an
amendment to earlier commitments unveiled with the U.S. government
in November 2021.
GSK and Vir said they have received binding agreements for the
sale of about 1.7 million doses of sotrovimab worldwide.
Tuesday's agreement also includes the option for the U.S.
government to purchase further additional doses in the second
quarter of 2022.
Sotrovimab, which was granted emergency use authorization by the
U.S. Food and Drug Administration in May, is an investigational
single-dose intravenous infusion SARS-CoV-2 monoclonal
antibody.
Under the EUA, sotrovimab can be used for the treatment of
mild-to-moderate Covid-19 in adults and pediatric patients 12 and
older.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 11, 2022 07:55 ET (12:55 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
